Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Port Richey, Florida


Purpose:

The immune system normally fights infection, but in diseases like RA, the immune system may be overactive or act incorrectly, leading to inflammation, seen as such things as swelling and pain. Pfizer is developing CP-690,550 as a disease-modifying antirheumatic drug (DMARD-pronounced DEE-mard) for the treatment of RA. The purpose of this type of treatment is to control disease activity, improve symptoms (like swelling and pain), maintain normal, every-day functions and activities, improve physical, emotional, and mental well-being, and slow down joint damage.


Criteria:

Inclusion Criteria: - Subjects With Active RA Who Have Failed Therapy With Either Methotrexate Or A TNF Inhibitor Exclusion Criteria: - Current Therapy With Any DMARD Or Biologic


NCT ID:

NCT00147498


Primary Contact:

Study Director
Pfizer CT.gov Call Center
Pfizer


Backup Contact:

N/A


Location Contact:

Port Richey, Florida
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.